10x Genomics, Inc. (TXG) has been one of the most dramatic stories in life sciences in 2026. After a roughly 348% year-to-date surge, the single-cell and spatial biology tools maker pulled back sharply from its early-October peak, leaving investors asking whether a move back toward triple-digit territory is realistic. The central question here — whether TXG can reach $105 — is best examined through the lens of analyst targets, valuation, and the company's still-unproven path to profitability.
Roughly 18 to 19 analysts cover TXG, according to S&P Global and Zacks data. Their targets span a wide band from a low near $50 to a high near $110, with an overall average price target of approximately $77. Because that average sits only about 5% above the recent price — too small to pose a meaningful "can it reach" question — the central target used here is instead the average of the verified targets that sit above the current price. Those higher-end targets, which include a $100 target from an October 2026 Buy rating and the $110 top of the range, average out to roughly $105.
Ratings are skewed cautious rather than uniformly bullish: the Street is split between Strong Buy/Buy calls and a large Hold contingent, with no formal Sell ratings. Barclays, Argus Research, Jefferies, Stephens, William Blair, and Canaccord Genuity have carried constructive or initiating Buy-style views during 2026, while UBS, RBC, Piper Sandler, Citi, Cowen, and Leerink have maintained or initiated Hold ratings. The wide $50–$110 range reflects a genuine debate about whether 10x Genomics' new product cycle justifies its re-rated multiple.
As of the late-October 2026 close, TXG traded near $72.96, within a 52-week range of $12.34 to $102.81. Reaching $105 would require a rise of about 44%, a very large move by any conventional measure. Notably, however, the stock touched its $102.81 52-week high on October 6 before a sharp selloff erased roughly a quarter of its value within weeks, so $105 lies just above a level the market has already visited. The path toward it would likely depend on whether the company's Atera platform and spatial portfolio convert analyst enthusiasm into sustained instrument placements and consumables revenue, rather than renewed momentum alone.
Several verified factors could support a recovery toward $105. The company is a leader in single-cell analysis through its Chromium platform and in spatial biology through Visium and Xenium, and the newer Atera platform has given analysts a tangible growth driver to model. Positioning around AI-enabled drug discovery has attracted renewed interest, including a sizable 2026 purchase of roughly 222,000 shares by ARK Investment Management. The balance sheet remains comparatively clean, with modest debt relative to equity and a meaningful cash position, giving the company room to invest through its current losses.
The obstacles are substantial. 10x Genomics remains unprofitable, posting a trailing-twelve-month net loss of roughly $75 million on about $617 million in revenue, with EPS (earnings per share) around -$0.61. The stock's five-year beta near 2.0 underscores its volatility, and its valuation already reflects considerable optimism about future growth that has not yet materialized on the bottom line. Competition in single-cell and spatial genomics could pressure pricing, and any slowdown in academic or biopharma research spending would weigh directly on instrument demand.
The chart offers clear reference points. The $102.81 early-October high and the psychologically important $100 level form a durable resistance zone that a move toward $105 would need to clear. On the downside, the stock has repeatedly found support near the $67 area during October, a zone that has held through several sharp intraday declines. A sustained break below that support would undermine the bullish technical structure, while a reclaim of $100 would put the central target back in view.
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual analysts may apply different assumptions. The most important near-term catalyst is the company's third-quarter earnings report, confirmed for November 5, 2026, which will test the Street's revenue and guidance expectations. Investors should also watch for analyst target revisions, commentary on Atera adoption and consumables pull-through, any changes in institutional positioning, and broader risk appetite for unprofitable, high-beta growth stocks.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like TXG, such tools can help traders surface opportunities, monitor existing positions, and spot shifting trends more efficiently than manual chart review alone. Explore the signals to see how AI-driven analytics approach this and other tickers.
Whether 10x Genomics (TXG) can reach $105 depends less on sentiment than on execution. The target, derived from analyst targets above the current price, implies a roughly 44% advance from about $73 — a demanding climb, though one that merely retests territory the stock occupied in early October. Support comes from Atera, spatial biology momentum, and AI-adjacent demand, while unprofitability, a rich valuation, and intense volatility are the principal obstacles. With the average analyst target near $77 and individual estimates spanning $50 to $110, the Street itself is divided. The November earnings report and any guidance updates are the clearest near-term signposts for whether higher targets regain credibility.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TXG has been loosely correlated with BRKR. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if TXG jumps, then BRKR could also see price increases.
| Ticker / NAME | Correlation To TXG | 1D Price Change % | ||
|---|---|---|---|---|
| TXG | 100% | -3.31% | ||
| BRKR - TXG | 58% Loosely correlated | -6.46% | ||
| COIN - TXG | 56% Loosely correlated | -2.92% | ||
| CLSK - TXG | 54% Loosely correlated | -4.92% | ||
| RIOT - TXG | 54% Loosely correlated | +2.38% | ||
| PACB - TXG | 53% Loosely correlated | -5.08% | ||
More | ||||
| Ticker / NAME | Correlation To TXG | 1D Price Change % |
|---|---|---|
| TXG | 100% | -3.31% |
| Medical/Nursing Services industry (138 stocks) | 7% Poorly correlated | -1.46% |
| Health Services industry (239 stocks) | 6% Poorly correlated | -1.13% |